PAHC — Phibro Animal Health Corporation stock price, charts and financials
QT50Phibro Animal Health CorporationPhibro Animal Health Corporation (NASDAQ: PAHC) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 15.53 | EPS (ttm) | 2.34 | Insider Own | - | Shs Outstand | 40.54M | Perf Week | 6.76% |
| Market Cap | 1.47B | Forward P/E | 9.86 | EPS next Y | 3.68 | Insider Trans | -0.90% | Shs Float | 40.24M | Perf Month | 13.18% |
| Enterprise Value | 2.21B | PEG | 0.08 | EPS next Q | 0.72 | Inst Own | - | Short Float | 3.03% | Perf Quarter | -31.68% |
| Income | 95.14M | P/S | 0.98 | EPS this Y | 43.50% | Inst Trans | - | Short Ratio | 3.35 | Perf Half Y | -8.92% |
| Sales | 1.50B | P/B | 4.07 | EPS next Y | 10.20% | ROA | 6.59% | Short Interest | 1.22M | Perf YTD | -2.76% |
| Book/sh | - | P/C | 22.28 | EPS next 5Y | 13.04% | ROE | 29.49% | 52W High | 61.44 -39.53% | Perf Year | 30.12% |
| Cash/sh | - | P/FCF | 115.32 | EPS past 3/5Y | -0.55% 7.47% | ROIC | 11.38% | 52W Low | 26.16 42.03% | Perf 3Y | 145.81% |
| Dividend Est. | 0.48 (1.29%) | EV/EBITDA | 9.79 | Sales past 3/5Y | 11.22% 10.13% | Gross Margin | 32.49% | Volatility | 3.87% 3.91% | Perf 5Y | 49.44% |
| Dividend TTM | 0.48 (1.29%) | EV/Sales | 1.47 | EPS Y/Y TTM | 3783.33% | Oper. Margin | 12.27% | ATR (14) | 1.40 | Perf 10Y | 78.79% |
| Dividend Ex-Date | Sep 02, 2026 | Quick Ratio | 1.26 | Sales Y/Y TTM | 47.45% | Profit Margin | 6.35% | RSI (14) | 62.53 | Recom | 2.86 |
| Dividend Gr. 3/5Y | 0.00% 0.00% | Current Ratio | 3.17 | EPS Q/Q | 61.11% | SMA20 | 6.56% | Beta | 0.46 | Target Price | 49.00 |
| Payout | 20.43% | Debt/Eq | 2.18 | Sales Q/Q | 10.34% | SMA50 | 10.93% | Rel Volume | 0.58 | Prev Close | 36.33 |
| Employees | 2,475 | LT Debt/Eq | 2.57 | Earnings | Aug 26 | SMA200 | -14.77% | Avg Volume | 356.44K | Price | 37.15 |
| IPO Date | Apr 11, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 29.85% 5.14% | Net Debt/EBITDA | 3.25 | Volume | 205,472 | Change | 2.26% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-06-26 | Reiterated | Morgan Stanley | Equal Weight | $45 → $49 |
| Aug-28-25 | Reiterated | Morgan Stanley | Equal Weight | $26 → $34 |
| Jul-07-25 | Upgrade | JP Morgan | Neutral → Overweight | |
| Jun-25-25 | Reiterated | Morgan Stanley | Equal Weight | $20 → $26 |
| Apr-15-25 | Reiterated | Morgan Stanley | Equal Weight | $27 → $20 |
| Dec-21-22 | Reiterated | Roth Capital | Buy | $18 |
| Sep-16-22 | Reiterated | Barclays | Underweight | $17 |
| Aug-26-22 | Reiterated | Morgan Stanley | Equal Weight | $21 |
| Jul-25-22 | Downgrade | Barclays | Equal Weight → Underweight | |
| Jan-10-22 | Upgrade | Barclays | Underweight → Equal Weight |
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 6/30/2025 | FY 2024 6/30/2024 | FY 2023 6/30/2023 | FY 2022 6/30/2022 | FY 2021 6/30/2021 | FY 2020 6/30/2020 | FY 2019 6/30/2019 | FY 2018 6/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,501 | 1,296 | 1,018 | 978 | 942 | 833 | 800 | 828 | 820 | |
| Cost of Goods Sold Incl. D&A | 1,012 | 896 | 705 | 680 | 657 | 562 | 543 | 563 | 553 | |
| Gross Profit | 488 | 400 | 313 | 298 | 285 | 271 | 257 | 265 | 267 | |
| Selling, General and Administrative Excl. Other | 302 | 289 | 260 | 226 | 206 | 197 | 188 | 181 | 168 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 10 | |
| Other Operating Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12 | -10 | |
| Operating Income | 184 | 110 | 53 | 72 | 79 | 75 | 69 | 73 | 99 | |
| Interest Expense | 45 | 33 | 22 | 18 | 12 | 10 | 14 | 14 | 14 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -9 | -9 | -20 | 0 | 5 | 2 | 1 | 12 | 3 | |
| Net Income Before Taxes | 128 | 68 | 11 | 54 | 72 | 66 | 56 | 72 | 88 | |
| Income Taxes | 34 | 20 | 9 | 21 | 23 | 12 | 22 | 17 | 23 | |
| Consolidated Net Income | 95 | 48 | 2 | 33 | 49 | 54 | 34 | 55 | 65 | |
| Net Income From Continuing Operations | 95 | 48 | 2 | 33 | 49 | 54 | 34 | 55 | 65 | |
| Net Income | 95 | 48 | 2 | 33 | 49 | 54 | 34 | 55 | 65 | |
| EPS (Recurring) | 2.34 | 1.19 | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | |
| EPS (Basic, Before Extraordinaries) | 2.34 | 1.19 | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | |
| EPS (Diluted) | 2.33 | 1.19 | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | |
| EBITDA | 226 | 147 | 69 | 106 | 117 | 110 | 102 | 113 | 129 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 15.94 | 21.46 | 279.50 | 16.91 | 15.81 | 21.55 | 31.65 | 23.53 | 28.60 | |
| Price To Sales Ratio | 1.01 | 0.81 | 0.68 | 0.57 | 0.83 | 1.42 | 1.35 | 1.53 | 2.25 | |
| Gross Margin | 32.51 | 30.86 | 30.75 | 30.47 | 30.25 | 32.53 | 32.13 | 32.00 | 32.56 | |
| Operating Margin | 12.26 | 8.49 | 5.21 | 7.36 | 8.39 | 9.00 | 8.63 | 8.82 | 12.07 | |
| Net Margin | 6.33 | 3.70 | 0.20 | 3.37 | 5.20 | 6.48 | 4.25 | 6.64 | 7.93 | |
| Shares Outstanding | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 40 | 40 | |
| Market Capitalization | 1,523 | 1,047 | 688 | 562 | 784 | 1,184 | 1,077 | 1,271 | 1,842 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| CORCORAN E THOMAS | Director | May 29 '26 | Buy | 31.77 | 10,000 | 317,700 | 41,459 | Jun 02 |
| BENDHEIM JACK | President and CEO | May 07 '26 | Sale | 48.49 | 4,528 | 219,568 | 56,152 | May 07 |
| BENDHEIM JACK | President and CEO | May 06 '26 | Sale | 57.37 | 7,040 | 403,850 | 60,680 | May 07 |
| BENDHEIM JACK | President and CEO | May 05 '26 | Sale | 55.80 | 7,040 | 392,810 | 67,720 | May 07 |
| BENDHEIM JACK | President and CEO | Apr 30 '26 | Sale | 52.76 | 7,040 | 371,466 | 74,760 | Apr 30 |
| BENDHEIM JACK | President and CEO | Apr 29 '26 | Sale | 52.92 | 7,040 | 372,552 | 81,800 | Apr 30 |
| BENDHEIM JACK | President and CEO | Apr 28 '26 | Sale | 55.91 | 7,040 | 393,576 | 88,840 | Apr 30 |
| BENDHEIM JACK | President and CEO | Apr 23 '26 | Sale | 54.09 | 7,040 | 380,826 | 95,880 | Apr 23 |
| BENDHEIM JACK | President and CEO | Apr 22 '26 | Sale | 54.29 | 7,040 | 382,185 | 102,920 | Apr 23 |
| BENDHEIM JACK | President and CEO | Apr 21 '26 | Sale | 55.98 | 7,040 | 394,081 | 109,960 | Apr 23 |
| BENDHEIM JACK | President and CEO | Apr 16 '26 | Sale | 54.64 | 7,040 | 384,661 | 117,000 | Apr 16 |
| BENDHEIM JACK | President and CEO | Apr 15 '26 | Sale | 56.96 | 7,040 | 401,011 | 24,040 | Apr 16 |
| BENDHEIM JACK | President and CEO | Apr 14 '26 | Sale | 59.08 | 7,040 | 415,922 | 31,080 | Apr 16 |
| BENDHEIM JACK | President and CEO | Mar 31 '26 | Sale | 53.90 | 7,040 | 379,428 | 38,120 | Mar 31 |
| BENDHEIM JACK | President and CEO | Mar 30 '26 | Sale | 53.61 | 7,040 | 377,406 | 45,160 | Mar 31 |